Bavarian Nordic has initiated a Phase II study evaluating Prostvac as a treatment for patients with metastatic castration-resistant prostate cancer.
The multicentre, randomised Phase II study will compare Prostvac followed by docetaxel (chemotherapy) versus docetaxel alone.
Go deeper with GlobalData
Patients in the Prostvac arm will receive an accelerated treatment with Prostvac followed by docetaxel and prednisone, while those in control arm will receive upfront docetaxel and prednisone.
The study is expected to enrol 144 patients by 2012.
The primary endpoint of the study is to assess the overall survival.
Secondary endpoints include evaluation of prostate-specific antigen (PSA) response rates, evaluation of the association between development of PSA-specific immune responses, time to progression and overall survival in patients treated with these regimens.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
